Ausgabe 6/2021
Inhalt (16 Artikel)
Acknowledgement to Referees
Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments
Christine Blome, Matthias Augustin, Toni Maria Klein
Psychosocial Effects of Vitiligo: A Systematic Literature Review
Khaled Ezzedine, Viktoria Eleftheriadou, Heather Jones, Kristen Bibeau, Fiona I. Kuo, Daniel Sturm, Amit G. Pandya
Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons
Anne Sofie Frølunde, Jacob Pontoppidan Thyssen, Mette Deleuran, Christian Vestergaard
The Use of Lasers and Light Devices in Acne Management: An Update
Monica K. Li, Chaocheng Liu, Jeffrey T. S. Hsu
Investigational Treatments for Epidermolysis Bullosa
Ping-Chen Hou, Han-Tang Wang, Stasha Abhee, Wei-Ting Tu, John A. McGrath, Chao-Kai Hsu
Sunscreens and Photoaging: A Review of Current Literature
Linna L. Guan, Henry W. Lim, Tasneem F. Mohammad
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation
Nada Elbuluk, Pearl Grimes, Anna Chien, Iltefat Hamzavi, Andrew Alexis, Susan Taylor, Noelani Gonzalez, Jonathan Weiss, Seemal R. Desai, Sewon Kang
Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions
Marissa Contento, Abigail Cline, Marian Russo
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
Scott Guenthner, Wendy McFalda, Melita Tate, Kimberly Eads, Jayson Rieger, David K. Glover, Cynthia Willson, Pamela Rumney, Ted Rosen, Jennifer Andres, Melissa Olivadoti
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
Yan Zhao, Litao Zhang, Yangfeng Ding, Xiaohua Tao, Chao Ji, Xiuqin Dong, Jianyun Lu, Liming Wu, Rupeng Wang, Qianjin Lu, Aik Han Goh, Rongjun Liu, Zhiguo Zhang, Jianzhong Zhang
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020
Patrick M. Jedlowski, Mahdieh F. Jedlowski, Maryam T. Fazel
Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
Emma Borg, Henrik Thoning
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”
Tiago Torres, Andrea Chiricozzi, Luis Puig
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin L. Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Min Zhang, Saleem A. Farooqui, William Romero, Andrew J. Thorpe, Ricardo Rojo, Susan Johnson